"Serious" deficiencies in manufacturing practices at a single contract manufacturer in India, MJ Biopharm, forced eight pharma companies to recall generic products in the UK. Although pharma outsourcing is becoming more popular these days, incidents like this will remind companies that outsourcing contracts demand vigilant supervision in order for them to be successful and worthwhile.

For more information, please see: http://www.fiercepharma.com/story/contract-manufacturer-recall-slams-8-drugmakers/2009-07-06